Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JNJ

Johnson & Johnson

Mar 13 • 04:00PM ET

162.99

Dollar change +0.14
Percentage change 0.09	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: LLY PFE MRK AMGN BMY NVS ABBV GSK AZN MDT

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM DGRO IWD

Scroll to Statements

Index	DJIA, S&P 500	P/E	28.11	EPS (ttm)	5.80	Insider Own	0.13%	Shs Outstand	2.41B	Perf Week	-1.71%
Market Cap	392.42B	Forward P/E	14.76	EPS next Y	11.04	Insider Trans	-0.62%	Shs Float	2.40B	Perf Month	4.39%
Income	14.07B	PEG	5.56	EPS next Q	2.65	Inst Own	73.09%	Short Float	0.96%	Perf Quarter	8.95%
Sales	88.82B	P/S	4.42	EPS this Y	5.73%	Inst Trans	0.71%	Short Ratio	2.51	Perf Half Y	-2.62%
Book/sh	29.70	P/B	5.49	EPS next Y	4.65%	ROA	8.09%	Short Interest	23.10M	Perf Year	1.09%
Cash/sh	10.19	P/C	16.00	EPS next 5Y	5.06%	ROE	20.06%	52W Range	140.68 - 169.99	Perf YTD	12.70%
Dividend Est.	5.02 (3.08%)	P/FCF	19.78	EPS past 5Y	0.55%	ROI	13.61%	52W High	-4.12%	Beta	0.49
Dividend TTM	4.96 (3.04%)	Quick Ratio	0.86	Sales past 5Y	2.03%	Gross Margin	68.71%	52W Low	15.86%	ATR (14)	2.87
Dividend Ex-Date	Feb 18, 2025	Current Ratio	1.11	EPS Y/Y TTM	3.69%	Oper. Margin	23.52%	RSI (14)	55.22	Volatility	1.55% 1.70%
Employees	138100	Debt/Eq	0.53	Sales Y/Y TTM	-4.51%	Profit Margin	15.84%	Recom	2.17	Target Price	169.61
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-15.14%	Payout	84.80%	Rel Volume	0.57	Prev Close	162.85
Sales Surprise	0.40%	EPS Surprise	2.43%	Sales Q/Q	5.27%	Earnings	Jan 22 BMO	Avg Volume	9.22M	Price	162.99
SMA20	0.00%	SMA50	5.60%	SMA200	4.95%	Trades		Volume	5,274,069	Change	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183
Mar-02-22	Resumed	BofA Securities	Neutral	$185

Show Previous Ratings

Mar-13-25 08:19PM	Johnson & Johnson (JNJ): Breakout or Breakdown? Jim Cramer Says JNJ Must Fall for Market to Bottom (Insider Monkey)
06:16AM	FDA grants 510(k) clearance for J&J MedTechs Monarch Quest (Medical Device Network)
06:00AM	J&Js Monarch robot wins FDA nod for AI software update (MedTech Dive)
Mar-12-25 02:26PM	Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds (Insider Monkey)
09:47AM	Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy (Insider Monkey)
09:00AM	Loading…
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:15AM	A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV (BioPharma Dive)
Mar-11-25 12:07PM	Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025? (Insider Monkey)
11:21AM	Cramer's Mad Dash: Johnson & Johnson (CNBC TV)
10:20AM	Genmab says J&J not exercising option on HexaBody-CD38 (TipRanks)
09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com)
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
07:06AM	Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded (Investing.com)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily)
03:30PM	How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket (Benzinga)
03:14PM	Loading…
03:14PM	Johnson & Johnson's Ulcerative Colitis Drug Hits Key Trial Goals, Stock Rises (GuruFocus.com)
08:30AM	Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer (PR Newswire)
08:00AM	Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients (PR Newswire)
Mar-09-25 05:13PM	Is Johnson & Johnson (JNJ) the Best Performing Dividend Stock to Buy Now? (Insider Monkey)
Mar-08-25 11:21AM	CDC plans study into potential vaccines, autism connections, Reuters reports (TipRanks)
09:00AM	Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
12:13PM	Jim Cramer on Johnson & Johnson (JNJ): This Stock Has Been a Horse! (Insider Monkey)
09:03AM	Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' (Benzinga)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-06-25 08:00PM	Finance Executives Seek Stability Amid Erratic Tariff Shifts (The Wall Street Journal)
12:33PM	Is Johnson & Johnson (JNJ) the Best Holding Company Stock to Buy Right Now? (Insider Monkey)
11:47AM	CFOs Give Leadership Advice for Tumultuous Times (WSJ)
04:06AM	2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid (Motley Fool)
Mar-05-25 04:30PM	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results (Business Wire)
03:39PM	Loading…
03:39PM	Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out (Barrons.com)
02:36PM	Is Johnson & Johnson (JNJ) the Best Dividend Stock to Buy According to Billionaires? (Insider Monkey)
01:31PM	5 Big Biopharmaceutical Stocks That Are Finding Favor (Barrons.com)
09:45AM	What Trump's next batch of tariffs could mean for pharma industry (Yahoo Finance Video)
09:40AM	Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term (Zacks)
Mar-04-25 07:35PM	Johnson & Johnson (JNJ): Among Best Stocks To Invest In From Conservative Stock Portfolio (Insider Monkey)
05:26PM	Buy Johnson & Johnson (JNJ) Stock for Higher Highs? (Zacks)
04:15PM	Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations (Business Wire)
06:02AM	Unlocking Intrinsic Value: Analysis of Johnson & Johnson (GuruFocus.com)
04:06AM	Johnson & Johnson (JNJ): Among the Best S&P 500 Dividend Stocks to Buy Now (Insider Monkey)
Mar-03-25 05:45PM	Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today (Zacks)
05:46AM	FDA recall notice details J&J pause of Varipulse (MedTech Dive)
Mar-02-25 07:38AM	3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income (Motley Fool)
Mar-01-25 03:44PM	Johnson & Johnson (JNJ): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
05:51AM	3 Dividend Stocks That Are No-Brainer Buys Right Now (Motley Fool)
05:03AM	3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account (Motley Fool)
Feb-28-25 05:06AM	Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company (Motley Fool)
Feb-27-25 09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:38AM	Johnson & Johnson (JNJ): One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
Feb-26-25 04:12PM	Supreme Court Signals Minority Groups Get No Edge in Bias Suits (The Wall Street Journal)
03:37PM	Is Johnson & Johnson (JNJ) the Cheap Global Stock to Buy Right Now? (Insider Monkey)
03:34PM	Supreme Court Considers Reverse-Bias Lawsuits Amid DEI Backlash (The Wall Street Journal)
11:45AM	Johnson & Johnson (JNJ) Could Be a Great Choice (Zacks)
10:48AM	Johnson & Johnson (JNJ): Among the Top Dividend Stocks to Buy According to Hedge Funds (Insider Monkey)
04:39AM	Is Johnson & Johnson (JNJ) the Best Retirement Stock to Buy According to Hedge Funds? (Insider Monkey)
Feb-25-25 06:42PM	J&J sues Samsung Bioepis over surreptitious breach of Stelara biosimilar contract (Pharmaceutical Technology)
05:45PM	Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note (Zacks)
09:49AM	Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson (GuruFocus.com)
09:43AM	Johnson & Johnson (JNJ) Ranked 4th Best S&P 500 Dividend Aristocrat According to Hedge Funds (Insider Monkey)
06:38AM	J&Js potential neurovascular exit: implications for market dynamics (Medical Device Network)
Feb-24-25 10:06AM	90% of Gen Z Tie Clear Vision to Self-confidence, According to Acuvue (WWD)
09:27AM	Is Johnson & Johnson (JNJ) the Best DRIP Stock to Own Now? (Insider Monkey)
07:30AM	2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream (Motley Fool)
Feb-23-25 03:02PM	Johnson & Johnson (JNJ): Among the Best Performing Dow Stocks So Far in 2025 (Insider Monkey)
Feb-22-25 03:00PM	European Banks Swarm Dollar Market For AT1 Debt: Credit Weekly (Bloomberg)
Feb-21-25 07:24PM	Analyst Report: Johnson & Johnson (Morningstar Research)
11:30AM	Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue? (Zacks)
07:52AM	Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term? (Insider Monkey)
07:00AM	TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis (PR Newswire)
03:25AM	Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income (Motley Fool)
Feb-19-25 05:45PM	Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why (Zacks)
12:29PM	Carlsberg, Johnson & Johnson Tap Europe Market for M&A Bonds (Bloomberg)
07:10AM	Q4 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:40AM	Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value (GuruFocus.com)
Feb-18-25 05:22PM	Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan (The Wall Street Journal)
10:23AM	Thames Waters Crucial Rescue Loan Approved by UK Judge (Bloomberg)
06:05AM	J&J begins crucial battle over $10 billion baby powder settlement (Reuters)
05:00AM	J&J resumes PFA cases, but analysts warn safety may hamper rollout (MedTech Dive)
Feb-17-25 06:37AM	Johnson & Johnson to resume market release of Varipulse catheter in US (Medical Device Network)
02:54AM	Why Johnson & Johnson (JNJ) Is One of the Best Drug Stocks to Buy Now (Insider Monkey)
Feb-15-25 01:00PM	Dividend Investor With $1.05 Million In Stocks And $36,600 Annual Payout Shares Portfolio 'Could These Picks Set You Up for Life?' (Benzinga)
12:28PM	Johnson & Johnson (JNJ): Among the Best Forever Stocks to Buy Right Now (Insider Monkey)
Feb-14-25 11:35AM	Jim Cramer on Johnson & Johnson (JNJ): Too Slow Growing (Insider Monkey)
08:00AM	J&Js High Hopes for Heart-Rhythm Device Grounded by Safety Concerns (The Wall Street Journal)
Feb-13-25 12:31PM	J&J stops Phase III trial of Sanofis E. Coli vaccine citing disappointing results (Clinical Trials Arena)
08:30AM	Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study (Benzinga)
08:05AM	New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases (PR Newswire)
07:30AM	Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead (Benzinga)
06:31AM	Sanofi to take $250M charge on study failure for E. coli vaccine (BioPharma Dive)
Feb-12-25 10:37AM	Johnson & Johnson (JNJ): Jim Cramer on The Greatest Health Care Stock of All Time (Insider Monkey)
09:18AM	Why Johnson & Johnson (JNJ) is the Best Medical Device Stock to Buy (Insider Monkey)
07:11AM	Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates (Benzinga)
Feb-11-25 02:27PM	Johnson & Johnson puts stroke care business up for sale (Financial Times)
06:02AM	Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson (GuruFocus.com)
Feb-09-25 05:30PM	Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself' (Benzinga)
12:30PM	Johnson & Johnson (JNJ) Among the Best Stocks to Buy for Financial Stability (Insider Monkey)
07:15AM	2 Stocks to Buy if There Is a Market Crash in 2025 (Motley Fool)
Feb-08-25 04:40AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Feb-07-25 09:00AM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
Feb-06-25 05:07AM	With uncertainty roiling Big Pharma, execs are placing lower-risk bets (Pharma Voice)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '24	Option Exercise	0.00	22,255	0	22,561	May 03 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience